Contribution of adrenal hormones to nicotine‐induced inhibition of synovial plasma extravasation in the rat

Publisher Website
Google Scholar
Abstract
In this study, we examined the mechanism(s) by which s.c. nicotine inhibits synovial plasma extravasation. We found that nicotine dose‐dependently inhibited bradykinin (BK)‐ and platelet activating factor (PAF)‐induced plasma extravasation. The effect of nicotine on both BK‐ and PAF‐induced plasma extravasation was attenuated by adrenal medullectomy. ICI‐118,551 (a selective β2‐adrenoceptor blocker) (30 μg ml−1, intra‐articularly) significantly attenuated the inhibitory action of high‐dose (1 mg kg−1) nicotine on BK‐induced plasma extravasation without affecting the inhibition by low‐ (0.01 μg kg−1) dose nicotine or that on PAF‐induced plasma extravasation by nicotine at any dose. This suggested that β2‐adrenoceptors mediate the inhibitory actions of high‐dose, but not low‐dose, nicotine. We also found that systemic naloxone (an opioid receptor antagonist) (two hourly injections of 1 mg kg−1, i.p.) attenuated the inhibitory action produced by all doses of nicotine on BK‐ or PAF‐induced plasma extravasation, suggesting the contribution of endogenous opioids. RU‐38,486 (a glucocorticoid receptor antagonist) (30 mg kg−1, s.c.) and metyrapone (a glucocorticoid synthesis inhibitor) (two hourly injections of 100 mg kg−1, i.p.) both attenuated the action of high‐dose nicotine without affecting that of low‐dose nicotine. Spinal mecamylamine (a nicotinic receptor antagonist) (0.025 mg kg−1, intrathecally, i.t.) attenuated the action of high‐dose, but not low‐dose, nicotine, suggesting that part of the action of high‐dose nicotine is mediated by spinal nicotinic receptors. Combined treatment with ICI‐118,551, naloxone and RU‐38,486 attenuated the action of low‐dose nicotine by an amount similar to that produced by naloxone alone but produced significantly greater attenuation of the effect of high‐dose nicotine when compared to the action of any of the three antagonists alone. British Journal of Pharmacology (1997) 120, 298–304; doi:10.1038/sj.bjp.0700884